Deals of the Week: Is Botox On The Block?
A pair of setbacks have sent Allergan’s stock price south, but will a buyer take advantage and buy it in a mega-deal? Also, Amgen and Servier team up in a CV deal, Forma pursues an asset-focused strategy in tandem with Cancer Research Technology, and Immunocore reveals an antibody deal with GSK.
You may also be interested in...
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy
uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.
In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.